ADV 6209

Drug Profile

ADV 6209

Alternative Names: ADV6209

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Advicenne
  • Developer Primex Pharmaceuticals
  • Class Benzodiazepines
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anaesthesia; Sedation

Most Recent Events

  • 05 Oct 2016 Preregistration for Anaesthesia (In children, In infants, In adolescents) in France, Finland, United Kingdom, Netherlands, Italy (PO)
  • 05 Oct 2016 Preregistration for Sedation (In adolescents, In children, In infants) in France, Finland, United Kingdom, Netherlands, Italy (PO)
  • 31 Aug 2016 Primex Pharmaceuticals announces intention to market ADV 6209 in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top